publication date: May. 3, 2019

Guest Editorial

Getting beyond the immunotherapy divide: a call to action

John Stewart

John H. Stewart

Associate director for clinical research, University of Illinois Cancer Center



Robert A. Winn

Director, University of Illinois Cancer Center


Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.

Otne could look no further than the ever-increasing numbers of lung cancer immunotherapy trials to see the excitement in the field of cancer. Many patients believe that the new immunotherapies are the “miracle drugs” of the 21st century, therapies that cure all cancers.

At times, patients will push physicians to give them the drugs even when there is little evidence of effectiveness in their specific cancer.

Unfortunately, the success of these miracle drugs has not, as of yet, reached many in the rural or urban communities. Denise Grady clearly articulated many of the issues associated with minorities and clinical trials in her 2016 New York Times article titled “In Cancer Trials, Minorities Face … Continue reading Getting beyond the immunotherapy divide: a call to action

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.